Please use this identifier to cite or link to this item: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/12871
Title: UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities
Authors: Staubach, P.
Bilo, B.
Fluhr, J. W.
Krause, K.
Kulthanan, K.
Salman, A.
Katelaris, C.
Bernstein, J. A.
Maurer, M.
Mann, C.
Affiliates: Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology IFA, Charit� - Universit�tsmedizin Berlin, Berlin, Germany Fraunhofer Insitute for Translational Medicine and Pharmacology, ITMP Berlin, Immunology and Allergology IA, Berlin, Germany Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Department of Dermatology, Ac�badem University School of Medicine, Istanbul, Turkey Department of Medicine, Campbelltown Hospital and Western Sydney University Sydney, Campbelltown, Australia Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Issue Date: 2024
Journal: Journal of Dermatological Treatment
Publisher: Taylor and Francis Ltd.
Abstract: Background: There is a lack of real-life safety data on treatment options for chronic urticaria in the presence of comedication and comorbidities. Methods: We present a single-center UCARE pilot study of 212 outpatients with chronic urticaria. Patients were divided into three groups according to different CU therapies according to international guidelines. Results: Of 212 patients, 108 (mean age 48.9 years, 71.3% female) had 59 comorbidities, including cardiovascular, autoimmune and malignant diseases. Patients were followed for a mean of 24.6 months (SD � 21.3). Urticaria therapies were divided into three groups: A: 105 (97.2%) with omalizumab and 2nd generation antihistamines), B: 16 patients (14.8%): dual therapy with antihistamines and cyclosporine in 10 (9.3%), montelukast in five (4. 6%), dapsone in four (3.7%), hydroxychloroquine in one patient (0.9%), C: 12 (11.1%) patients received a third drug for 4.9 months (SD � 3.2) and one quadruple therapy (2.1 months). 10 out of 12 (83.3%) patients received montelukast, two (16.7%) cyclosporine, two (16.7%) dapsone and one (8.3%) hydroxychloroquine as a third drug for chronic urticaria. Conclusions: Combining treatment modalities for chronic urticaria and comorbidities are available and feasible with a good safety profile. � 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
URI: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/12871
ISSN: 09546634 (ISSN)
Digital object identifier: 10.1080/09546634.2024.2329784
Appears in Collections:Camden and Campbelltown Hospitals

Files in This Item:
There are no files associated with this item.


Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing